文献速递腹部MR

基于MRI的生境分析预测直肠癌新辅助放化疗后病理缓解:一项多中心研究

MRI-based habitat analysis for pathologic response prediction after neoadjuvant chemoradiotherapy in rectal cancer: a multicenter study.
PubMed 文献 · Eur Radiol · 2025-09-22

该多中心研究纳入三家医院1021例直肠癌患者,利用深度学习自动分割高分辨率MRI全病灶并提取生境特征,构建临床、瘤内异质性、影像组学及融合模型预测新辅助放化疗后病理缓解。融合模型在四个队列中AUC为0.867、0.851、0.852、0.818,优于临床模型,且融合模型分层组间无病生存期有显著差异。

要点

  • 融合模型预测病理缓解的AUC在四个队列中分别为0.867、0.851、0.852、0.818。
  • 融合模型与瘤内异质性模型之间AUC无显著差异。
  • 融合模型分层后良好与不良缓解组间无病生存期差异有统计学意义(四个队列均p<0.05)。

核心结论

  • 结合临床因素、影像组学特征和瘤内异质性特征的融合模型可能有助于预测接受新辅助放化疗的直肠癌患者的病理缓解。

研究设计与样本

  • 多中心研究,三家医院共1021例直肠癌患者,分为训练集和测试集(n=319)、内部验证集(n=317)、外部验证集1(n=158)和外部验证集2(n=227);采用深度学习在高分辨率MRI上自动分割全病灶,简单线性迭代聚类划分肿瘤亚区并提取影像组学特征,确定反映肿瘤生态系统多样性的最佳聚类数,构建临床、瘤内异质性、影像组学和融合四种模型并评估性能。

诊断标准与关键数值

  • Delong检验显示融合模型AUC在四个队列分别为0.867、0.851、0.852、0.818,影像组学模型为0.831、0.694、0.753、0.705,瘤内异质性模型为0.790、0.786、0.759、0.722,均优于临床模型的0.790、0.605、0.735、0.704;融合模型与瘤内异质性模型之间无显著差异。

临床应用与阅片要点

  • 融合模型整合临床特征、影像组学特征和瘤内异质性特征,可用于预测直肠癌患者新辅助放化疗后的缓解,可能有助于个体化治疗策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To investigate MRI-based habitat analysis for its value in predicting pathologic response following neoadjuvant chemoradiotherapy (nCRT) in rectal cancer (RC) patients.

MATERIALS AND METHODS: 1021 RC patients in three hospitals were divided into the training and test sets (n = 319), the internal validation set (n = 317), and external validation sets 1 (n = 158) and 2 (n = 227). Deep learning was performed to automatically segment the entire lesion on high-resolution MRI. Simple linear iterative clustering was used to divide each tumor into subregions, from which radiomics features were extracted. The optimal number of clusters reflecting the diversity of the tumor ecosystem was determined. Finally, four models were developed: clinical, intratumoral heterogeneity (ITH)-based, radiomics, and fusion models. The performance of these models was evaluated. The impact of nCRT on disease-free survival (DFS) was further analyzed.

RESULTS: The Delong test revealed the fusion model (AUCs of 0.867, 0.851, 0.852, and 0.818 in the four cohorts, respectively), the radiomics model (0.831, 0.694, 0.753, and 0.705, respectively), and the ITH model (0.790, 0.786, 0.759, and 0.722, respectively) were all superior to the clinical model (0.790, 0.605, 0.735, and 0.704, respectively). However, no significant differences were detected between the fusion and ITH models. Patients stratified using the fusion model showed significant differences in DFS between the good and poor response groups (all p < 0.05 in the four sets).

CONCLUSION: The fusion model combining clinical factors, radiomics features, and ITH features may help predict pathologic response in RC cases receiving nCRT.

KEY POINTS: Question Identifying rectal cancer (RC) patients likely to benefit from neoadjuvant chemoradiotherapy (nCRT) before treatment is crucial. Findings The fusion model shows the best performance in predicting response after neoadjuvant chemoradiotherapy. Clinical relevance The fusion model integrates clinical characteristics, radiomics features, and intratumoral heterogeneity (ITH)features, which can be applied for the prediction of response to nCRT in RC patients, offering potential benefits in terms of personalized treatment strategies.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Chen Q, Zhang Q, Li Z, et al. MRI-based habitat analysis for pathologic response prediction after neoadjuvant chemoradiotherapy in rectal cancer: a multicenter study. Eur Radiol. 2025. PMID: 40981989. doi:10.1007/s00330-025-11997-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。